Brief: Innate Pharma Announces Licensing Of Fourth Natural Killer Cell Engager In Oncology To Sanofi

Innate Pharma SA

19/12/2023 06:17

Dec 19 (Reuters) - Innate Pharma SA  IPH.PA :
    * INNATE PHARMA ANNOUNCES LICENSING OF A FOURTH NATURAL
KILLER
CELL ENGAGER IN ONCOLOGY TO SANOFI
    * SANOFI TO EXERCISE ONE OPTION TO LICENSE A NEW ANKET®
PROGRAM
FROM INNATE; AFTER A RESEARCH COLLABORATION PERIOD, SANOFI WILL
BE RESPONSIBLE FOR ALL DEVELOPMENT, MANUFACTURING AND
COMMERCIALIZATION OF PROGRAM
    * IS ELIGIBLE FOR UP TO EUR 1.35BN TOTAL IN PRECLINICAL,
CLINICAL,
REGULATORY AND COMMERCIAL MILESTONES PLUS ROYALTIES ON POTENTIAL
NET SALES.

Source text for Eikon:  ID:nBw10JStPa 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))